Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + capecitabine + erlotinib
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination regimen consisting of three drugs: bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A); capecitabine, an oral prodrug of 5-fluorouracil that inhibits DNA synthesis; and erlotinib, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. The combination is under investigation for the treatment of advanced cancers, particularly pancreatic cancer. Bevacizumab inhibits angiogenesis by blocking VEGF-A, thereby reducing tumor blood supply. Capecitabine interferes with DNA synthesis in rapidly dividing cells. Erlotinib blocks EGFR signaling pathways involved in cell proliferation and survival. Together, these agents target both tumor cell proliferation and the supporting vasculature[1][2].
- Brand names
- Avastin (bevacizumab)Xeloda (capecitabine)Tarceva (erlotinib)
- Other names
- bevacizumab + capecitabine + erlotinib
02
Targets
EGFR (Epidermal growth factor receptor)VEGFA (Vascular endothelial growth factor A)TS (Thymidylate synthase)
Beyond the preview
Go deeper on bevacizumab + capecitabine + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + capecitabine + erlotinib.